<DOC>
	<DOCNO>NCT02170337</DOCNO>
	<brief_summary>A randomized , double-blind , ascend multiple dose study healthy volunteer subject chronic rhinosinusitis nasal polyp</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics AMG 282 Healthy Subjects Subjects With Chronic Rhinosinusitis With Nasal Polyps</brief_title>
	<detailed_description />
	<mesh_term>Polyps</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<criteria>Healthy Volunteers : Healthy male females witha BMI 18.0 32.0 kg/m2 , inclusive subject evidence clinically significant disorder , condition disease would pose risk subject safety interfere study evaluation , procedure , completion . Subjects chronic rhinosinusitis nasal polyp ( CRSwNP ) : diagnosis CRSwNP ( inflammation nose paranasal sinus characterize adult 2 symptom , 1 either nasal blockage nasal discharge and/or facial pain and/or reduce smell great 12 week ) bilateral nasal polyp grade 3 4 Forced Expiratory Volume ( FEV1 ) &lt; /= 70 % Asthma exacerbation require systemic corticosteroid treatment hospitalization &gt; 24h treatment asthma , within 3 month prior screen dose great 1000 Î¼g fluticasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>